Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C30H41N3O5 |
| Molecular Weight | 523.6636 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC3=C(N(CCCOC(=O)C(C)(C)C)C=C3)C(=C2)C(N)=O
InChI
InChIKey=CTMYLDUPTAZFCT-OAQYLSRUSA-N
InChI=1S/C30H41N3O5/c1-6-36-25-10-7-8-11-26(25)37-17-13-32-21(2)18-22-19-23-12-15-33(27(23)24(20-22)28(31)34)14-9-16-38-29(35)30(3,4)5/h7-8,10-12,15,19-21,32H,6,9,13-14,16-18H2,1-5H3,(H2,31,34)/t21-/m1/s1
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9529MK8HWG
Created by
admin on Sat Dec 16 10:16:36 GMT 2023 , Edited by admin on Sat Dec 16 10:16:36 GMT 2023
|
PRIMARY | |||
|
9872508
Created by
admin on Sat Dec 16 10:16:36 GMT 2023 , Edited by admin on Sat Dec 16 10:16:36 GMT 2023
|
PRIMARY | |||
|
KRG-3332(FREE BASE)
Created by
admin on Sat Dec 16 10:16:36 GMT 2023 , Edited by admin on Sat Dec 16 10:16:36 GMT 2023
|
PRIMARY | Originator: Kissei Pharmaceutical; Class: Antiglaucomas; Mechanism of Action: Alpha 1a adrenergic-receptor antagonists; Highest Development Phase: Discontinued for Glaucoma use | ||
|
239463-68-4
Created by
admin on Sat Dec 16 10:16:36 GMT 2023 , Edited by admin on Sat Dec 16 10:16:36 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
